NCT06104488View on ClinicalTrials.gov

A Study of Avutometinib for People With Solid Tumor Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

October 20, 2029

Study Completion Date

October 20, 2029

Conditions
Refractory CancerCNS TumorsCNS Tumor, AdultCNS Tumor, ChildhoodMAP Kinase Family Gene MutationNF1Plexiform NeurofibromaLow-grade GliomaOptic Pathway GliomasNeuroblastomaPrimary Brain TumorSolid TumorSolid Tumor, AdultSolid CarcinomaCentral Nervous System Tumor
Interventions
DRUG

Avutometinib

Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

30322

RECRUITING

Children's Healthcare of Atlanta (Data Collection Only), Atlanta

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER